[A case of advanced oral squamous cell carcinoma responding to concurrent radiotherapy with S-1]

Gan To Kagaku Ryoho. 2007 May;34(5):745-7.
[Article in Japanese]

Abstract

A 68-year-old patient with advanced oral squamous cell carcinoma (T3N2bM0, Stage IVA) was treated by concurrent radiotherapy with S-1.S-1 (120 mg/body/day) was orally administered for 4 weeks followed by a 2-week rest period as one course, and radiation was given (1.8 Gy/day; 5 days/week) for a total of 61.2 Gy. After 61.2 Gy radiation and two courses of S-1, the primary region showed a complete response (CR), and that the tumor cell was not identified as a result of biopsy. In addition, the metastatic lymph nodes in the neck were no longer seen on head and neck computed tomography (CT). Although the patient is still taking UFT, he is well with no signs of recurrence 27 months from the initial treatment.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / radiotherapy*
  • Carcinoma, Squamous Cell / secondary
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Drug Combinations
  • Humans
  • Lymph Nodes / pathology
  • Lymphatic Metastasis
  • Male
  • Mouth Neoplasms / drug therapy*
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / radiotherapy*
  • Oxonic Acid / therapeutic use*
  • Radiotherapy Dosage
  • Remission Induction
  • Tegafur / therapeutic use*

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid